📰 Kumar Budur News
Page 2 - Kumar Budur News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Kumar Budur. Real-time updates on events, politics, business and more.
February 20, 2024
The FDA has granted Orphan Drug designation to Harmony Bioscience’s pitolisant for the treatment of Prader-Willi syndrome.
December 9, 2023
Phase 2 study results reveal pitolisant significantly improved daytime sleepiness and fatigue in myotonic dystrophy type 1 patients.
December 7, 2023
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal...
December 5, 2023
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
November 6, 2023
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Good morning. My name is Ashley, and I’ll be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Third Quater 2023 Financial Results Conference Call. All participant lines have been placed on mute to […]
October 31, 2023
HRMY earnings call for the period ending September 30, 2023.
October 13, 2023
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
October 13, 2023
Harmony Biosciences Holdings Inc shares sank 38% to $18.66 in late-morning trading on Friday after the pharmaceutical company reported topline results from...
October 13, 2023
Treatment with pitolisant achieved robust clinical response in patients with idiopathic hypersomnia, according to phase 3 study results.
October 13, 2023
The INTUNE study of pitolisant for IH showed no statistical significance against placebo for daytime sleepiness in the withdrawal phase.